Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SZ Usmani, A Hoering, S Ailawadhi, R Sexton… - The Lancet …, 2021 - thelancet.com
Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …
被引用次数：99 相关文章

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SWOG1211 Trial Investigators - The Lancet …, 2021 - mdanderson.elsevierpure.com
Background: The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SWOG1211 Trial Investigators - The Lancet …, 2021 - mayoclinic.elsevierpure.com
Background: The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …
[HTML] nih.gov

[HTML][HTML] Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary …

SZ Usmani, A Hoering, S Ailawadhi… - The Lancet …, 2021 - ncbi.nlm.nih.gov
Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SZ Usmani, A Hoering, S Ailawadhi, R Sexton… - The Lancet …, 2021 - Elsevier
Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SZ Usmani, A Hoering, S Ailawadhi… - The Lancet …, 2020 - europepmc.org
Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SZ Usmani, A Hoering, S Ailawadhi, R Sexton, B Lipe… - 2021 - hero.epa.gov
BACKGROUND: The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …

[引用][C] Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary …

SZ Usmani, A Hoering, S Ailawadhi, R Sexton… - The Lancet …, 2021 - cir.nii.ac.jp
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with
untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase …

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a …

SZ Usmani, A Hoering, S Ailawadhi… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …